Sarepta Therapeutics is facing significant scrutiny after three patients died following administration of its gene therapies for muscular dystrophies. Two deaths involved Elevidys for Duchenne muscular dystrophy, and a third was associated with an investigational limb-girdle muscular dystrophy therapy. The FDA has requested Sarepta halt shipments of Elevidys for Duchenne muscular dystrophy and requires a black box warning for acute liver injury and acute liver failure. Sarepta has responded with a strategic restructuring, cutting approximately 36% of its workforce (about 500 jobs) to save $400 million annually and shifting its pipeline focus more heavily toward siRNA therapies. The company is developing enhanced immunosuppression regimens and conducting further studies to address safety concerns, while Elevidys remains on the market with warnings. This series of events has weighed on the company's stock, although recent cost-saving measures have been positively received by investors.